Dr. Kunz on the Impact of Lanreotide’s Approval for Neuroendocrine Tumors

0 Views
administrator
administrator
07/13/23

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next